Michael R. Convente, Ph.D., is currently serving as Associate Director, Portfolio Strategy & Intelligence at Regeneron Pharmaceuticals. At Regeneron, Dr. Convente serves on the Dupixent team and other programs in the immunology & inflammation therapeutic area, as well as serving on autoimmune and rare disease programs. Previously, Dr. Convente worked as a Biotechnology Equity Research Associate for Canaccord Genuity and as a Senior Medical Writer for Scientific Pathways. Dr. Convente earned his Ph.D. in Cell and Molecular Biology from the University of Pennsylvania Perelman School of Medicine and his B.A. in Molecular Biology and Biochemistry from Rutgers, The State University of New Jersey. While at Penn, Dr. Convente completed his thesis work in the lab of Dr. Eileen Shore, investigating the inflammatory contributions to the ultra-rare disease Fibrodysplasia Ossificans Progressiva.